• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl represents Aegirbio in rights issue of units prior too listing on Nasdaq First North Growth Market

  • Home
  • Latest news
  • Cases and transactions
  • 2020
  • Lindahl represents Aegirbio in rights issue of units prior too listing on Nasdaq First North Growth Market

Aegirbio is conducting a fully guaranteed rights issue of units to private and institutional investors in Sweden. Full subscription to the issue will raise approximately SEK 15 million before costs. In the event of high demand, the board of directors has the opportunity to allocate additional units equivalent to up to SEK 2.25 million before the deduction of issue costs. Should the issue be fully subscribed and all TO1 warrants are exercised within the scope of the offer and any additional allotment, the company may raise an additional SEK 20.7 million before the deduction of issue costs.

Aegirbio intends to apply to have the company’s shares and warrants listed on the Nasdaq First North Growth Market. The registration period for participating in the offer is 1-15 June 2020, with the provisional first day of trading set for 26 June 2020.

The purpose of the offer is to finance the continued development of Aegirbio into a market-driven company, initially through the continued commercialisation of its product MoNATor. MoNATor is a dose-monitoring laboratory developed test (LDT) designed for the US market, initially commercialised for use with biomedicine Natalizumab (Tysabri) in the treatment of multiple sclerosis.

Lindahl has provided Aegirbio with legal counsel in conjunction with the issue through a team consisting of Monica Lagercrantz and Dennis Westermark (responsible partners), Ola Svanberg, Nicklas Bexelius and Lisa Liljekvist. Eminova Partners AB has provided financial advice in conjunction with the issue.

 

Corporate finance

Lindahl's Corporate Finance team consists of 85 lawyers and is one of the largest in Sweden. Our solid experience and leading market position gives us the opportunity to participate in large projects with complex issues where we help clients to build an understanding of market conditions, challenges, opportunities and risks. We are top ranked in surveys based on client satisfaction and are constantly working to develop our consulting.

Visit page

Capital markets and public M&A

Lindahl’s competence group for capital markets and public M&A advises Swedish and foreign listed companies and other companies, venture capital companies, banks, investment banks, stockbrokers and other operators in various transactions and matters within the area of capital markets and public M&A.

Visit page

Contact

  • Monica Lagercrantz

    Stockholm

    monica.lagercrantz@lindahl.se +46 761 269 109
  • Dennis Westermark

    Stockholm

    dennis.westermark@lindahl.se +46 761 269 102
  • Ola Svanberg

    Stockholm

    ola.svanberg@lindahl.se +46 761 269 115
  • Lisa Liljekvist

    Stockholm

Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm reception.stockholm@lindahl.se +46 8 527 70 800
  • Göteborg reception.goteborg@lindahl.se +46 31 799 10 00
  • Malmö reception.malmo@lindahl.se +46 40 664 66 50
  • Uppsala reception.uppsala@lindahl.se +46 18 16 18 50
  • Örebro reception.orebro@lindahl.se +46 19 20 89 00
  • Helsingborg reception.helsingborg@lindahl.se +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience